This article is more than 5 years old. Information may no longer be current.

Roche posts 8% rise in first-quarter sales

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BASEL, Switzerland — Roche reported total sales of 11.6 billion Swiss francs ($10.09 billion) during the first quarter, representing an 8% rise compared with sales reported during last year's first quarter. Roche partially ascribed this growth to strong sales in the company's ophthalmology division.

Roche's pharmaceuticals division reported first quarter sales totaling 9.2 billion Swiss francs ($8 billion), also representing an 8% gain over sales from the same period last year.

First-quarter sales of Avastin (bevacizumab) increased 30% to 1.5 billion Swiss francs ($1.3 billion), and sales of Lucentis (ranibizumab) in the United States rose 21% to 279 million Swiss francs ($243 million), according to the release. Roche attributed the rise in ranibizumab sales to an increasing injections-per-patient ratio, as well as improvements in the market environment.

Roche plans to update its full-year outlook to include the impact of the Genentech transaction when the company releases its half-year results in July.